找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Recent Advances in Musculoskeletal Oncology; Atsumasa Uchida,Keiro Ono Conference proceedings 1992 Springer Japan 1992 bone.cancer.chemoth

[復(fù)制鏈接]
樓主: vein220
21#
發(fā)表于 2025-3-25 04:35:27 | 只看該作者
22#
發(fā)表于 2025-3-25 11:11:12 | 只看該作者
23#
發(fā)表于 2025-3-25 14:06:50 | 只看該作者
Principles for Designing Scientific Investigations of Orthopedic Malignanciess. Since tumors of the bone or soft tissue are rare, multi-institutional study is indispensable. One example, chemotherapy of osteosarcoma, is reviewed and principles for conducting a clinical investigation are described.
24#
發(fā)表于 2025-3-25 16:06:12 | 只看該作者
Preoperative Chemotherapy for the Treatment of Osteosarcomae most important prognostic factor. The aims of preoperative chemotherapy are (1) to control micrometastasis, (2) to control the primary tumor, and (3) to assess the effectiveness of the drugs used by grading of primary tumor necrosis.
25#
發(fā)表于 2025-3-25 22:47:16 | 只看該作者
Intra-Arterial Cisplatin Chemotherapy for Osteogenic Sarcomay has been tried in many cancer centers [1–3], with the resultant benefits of controlling micrometastasis, permitting the analysis of the response of the tumor to chemotherapy, and providing a better chance to save the endangered limb by reducing and consolidating the tumor volume [4]. Intra-arteria
26#
發(fā)表于 2025-3-26 02:08:04 | 只看該作者
Clinical Study of Recombinant Human Granulocyte Colony-Stimulating Factor in Patients Undergoing Intently recombinant forms of four human hematopoietic colony-stimulating factors have been purified [1–3], and their potential clinical application seem to be very promising for prevention of bone marrow suppression by chemotherapy. Reports on the effect of recombinant human granulocyte colony-stimula
27#
發(fā)表于 2025-3-26 05:57:09 | 只看該作者
Future Directions in the Management of Malignant Bone Tumors survival rate of patients with primary malignant bone tumors. There is some evidence that current chemotherapy programs have reached a plateau in their effect on survival, and that further improvements are going to be difficult both to obtain and to detect. This chapter describes some of the remain
28#
發(fā)表于 2025-3-26 10:53:48 | 只看該作者
29#
發(fā)表于 2025-3-26 15:27:02 | 只看該作者
30#
發(fā)表于 2025-3-26 17:41:46 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-21 03:07
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
清远市| 光泽县| 泸水县| 长治县| 错那县| 大荔县| 惠东县| 靖州| 全南县| 西丰县| 来宾市| 孝义市| 瓮安县| 岑溪市| 灵川县| 苍溪县| 克拉玛依市| 乌苏市| 江北区| 武清区| 韶关市| 木兰县| 固镇县| 阿合奇县| 海口市| 昭觉县| 综艺| 伊宁市| 屏边| 湟源县| 融水| 宣汉县| 黔江区| 岐山县| 沂水县| 镇沅| 永泰县| 泌阳县| 禄劝| 芜湖市| 桃江县|